A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma
Clinical trial NCT06586294 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06586294
- Sponsor
- Akeso
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-10
- Primary completion
- 2026-07-01
- Enrollment
- 294
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.